Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01088997 |
|
Recruitment Status :
Terminated
(Inadequate enrollment)
First Posted : March 18, 2010
Results First Posted : July 12, 2016
Last Update Posted : July 12, 2016
|
Sponsor:
Children's Hospital of Philadelphia
Collaborators:
University of Pennsylvania
Bedford Pharmaceuticals
American Medical Association
Thrasher Research Fund
Information provided by (Responsible Party):
Children's Hospital of Philadelphia
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Brief Summary:
The purpose of this pilot study is to determine a safe dose of milrinone to use in a larger study of babies with persistent pulmonary hypertension of the newborn (PPHN).
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Persistent Fetal Circulation Syndrome | Drug: Milrinone Lactate | Not Applicable |
Persistent pulmonary hypertension of the newborn (PPHN) is a condition in which the pulmonary vasculature fails to relax after birth resulting in severe hypoxemia. This condition has a high rate of mortality and morbidity. The current standard of care is treatment with inhaled nitric oxide (iNO). However, for many babies this treatment does not provide sufficient improvement in oxygenation.
In this study, subjects already receiving nitric oxide will be randomized to one of two dosing regimens of milrinone. They will receive milrinone IV for 24 hours and will be monitored for 24 hours afterwards. During this time, milrinone assays will be performed by blood sampling. Echocardiograms will also be performed to explore the pharmacodynamics of milrinone. Safety monitoring will be performed.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 12 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Milrinone Pharmacokinetics and Pharmacodynamics in Newborns With Persistent Pulmonary Hypertension of the Newborn - a Pilot Study to Enable a Randomized Trial of Intervention |
| Study Start Date : | June 2010 |
| Actual Primary Completion Date : | February 2013 |
| Actual Study Completion Date : | May 2015 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Pulmonary Hypertension
| Arm | Intervention/treatment |
|---|---|
|
Experimental: High Dose Milrinone
Subjects will receive a bolus intravenous (IV) infusion of 50 mcg/kg/min of milrinone lactate over 1 hour followed by a continuous IV infusion of 0.5 mcg/kg/min milrinone lactate over 24 hours. After completion of infusion, subjects will be monitored for an additional 24 hours.
|
Drug: Milrinone Lactate
Milrinone lactate will be given first as an IV bolus over one hour at the assigned dose level, followed by a 24 hour IV infusion at the assigned dose level.
Other Name: Milrinone |
|
Experimental: Low Dose Milrinone
Subjects will receive a bolus intravenous (IV) infusion of 20 mcg/kg/min of milrinone lactate over 1 hour followed by a continuous IV infusion of 0.2 mcg/kg/min milrinone lactate over 24 hours. After completion of infusion, subjects will be monitored for an additional 24 hours.
|
Drug: Milrinone Lactate
Milrinone lactate will be given first as an IV bolus over one hour at the assigned dose level, followed by a 24 hour IV infusion at the assigned dose level.
Other Name: Milrinone |
Primary Outcome Measures :
- Define Plasma Concentration-time Profile of Milrinone in Neonates With Persistent Pulmonary Hypertension of the Newborn (PPHN) - Clearance (CL, mL/Min) [ Time Frame: End of bolus dose, 15 minutes prior to end of infusion (EOI), at four time points after EOI with final sample at 12-15 hours after EOI (timing based on infant's weight) ]The schedule of milrinone pharmacokinetic (PK) sampling varied by weight to minimize blood sampling. For babies weighing less than 3kg, samples were drawn at the end of the bolus, 15 minutes prior to the end of infusion (EOI) and 20 minutes, 1, 2, 6 and 12 hours after EOI. For babies weighing 3kg or more, samples were drawn at the end of the bolus, 6 hours after start of infusion, 15 minutes prior to the EOI and 30 minutes, 1, 3, 9 and 15 hours after EOI. Milrinone plasma concentrations were determined using a validated high-performance mass spectrometry assay.
Secondary Outcome Measures :
- Change in Oxygenation Index (OI) From Baseline to up to 24 Hours After Start of Milrinone Infusion [ Time Frame: for up to 24 hours after start of infusion ]Oxygenation Index (mean airway pressure*Fraction of Inspired Oxygen/Partial Pressure of Oxygen in the blood) was calculated at baseline and every 6 hours after start of infusion until 12-24 hours after initiation of milrinone infusion.
- Change in Myocardial Performance Index (MPI) From Baseline to up to 24 Hours After Start of Milrinone Infusion [ Time Frame: Up to 24 hours after start of infusion ]An echocardiogram obtained while on milrinone was obtained with the goal of attempting to look for improvements in parameters associated with pulmonary hypertension. The primary parameter measured was the myocardial performance index (MPI). An Echocardiogram was performed at baseline (pre-infusion) and repeated 12-24 hours ater the initiation of the Milrinone infusion. Also known as the Tei index, the MPI is an index that incorporates both systolic and diastolic time intervals in expressing global systolic and diastolic ventricular function. Systolic dysfunction prolongs preejection (isovolumic contraction time, IVCT) and a shortening of the ejection time (ET). Both systolic and diastolic dysfunction result in abnormality in myocardial relaxation which prolongs the relaxation period (isovolumic relaxation time, IVRT). Normal value for MPI is 0.39+/-0.05 with dilated cardiomyopathy value of MPI at 0.59+/-0.10 (both units on a scale)
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | up to 10 Days (Child) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Gestational age > 34 weeks
- Post-natal age < 10 days
- Hypoxemia defined by: Oxygenation Index (OI) >15 (Mean Airway Pressure x Fraction of Inspired Oxygen (FiO2) x 100 /PaO2) as drawn from two post-ductal arterial blood gas samples (in-dwelling arterial catheter) taken at least 15 minutes apart. OR mechanically ventilated and with >75% FiO2 for >6 hours while on iNO
- Absence of congenital heart disease based on a two-dimensional echocardiogram and/or clinical assessment
- An in-dwelling arterial catheter to facilitate painless sampling
- Currently on iNO or plan to start iNO before enrollment
Exclusion Criteria:
- Lethal non-cardiac congenital anomalies including diaphragmatic hernia
- Clinically apparent bleeding; thrombocytopenia <30,000 or other laboratory evidence of coagulopathy
- Currently on extracorporeal membrane oxygenation (ECMO)or plan to initiate ECMO within 2 hours of enrollment
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01088997
Locations
| United States, Michigan | |
| Children's Hospital of Michigan/Hutzel Women's Hospital | |
| Detroit, Michigan, United States, 48201-2196 | |
| United States, Pennsylvania | |
| The Children's Hospital of Philadelphia | |
| Philadelphia, Pennsylvania, United States, 19104 | |
Sponsors and Collaborators
Children's Hospital of Philadelphia
University of Pennsylvania
Bedford Pharmaceuticals
American Medical Association
Thrasher Research Fund
Investigators
| Principal Investigator: | Haresh Kirpalani, MD | Children's Hospital of Philadelphia |
| Responsible Party: | Children's Hospital of Philadelphia |
| ClinicalTrials.gov Identifier: | NCT01088997 History of Changes |
| Other Study ID Numbers: |
09-007384 |
| First Posted: | March 18, 2010 Key Record Dates |
| Results First Posted: | July 12, 2016 |
| Last Update Posted: | July 12, 2016 |
| Last Verified: | June 2016 |
Keywords provided by Children's Hospital of Philadelphia:
|
Persistent pulmonary hypertension of newborn PPHN Persistent pulmonary hypertension Pulmonary hypertension Pulmonary hypertension of newborn |
Additional relevant MeSH terms:
|
Hypertension Hypertension, Pulmonary Persistent Fetal Circulation Syndrome Vascular Diseases Cardiovascular Diseases Lung Diseases Respiratory Tract Diseases Infant, Newborn, Diseases Milrinone |
Cardiotonic Agents Platelet Aggregation Inhibitors Vasodilator Agents Phosphodiesterase 3 Inhibitors Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs |